Author details

Full Name

Markus G Manz

Affiliation

ORCID

Career Start Year

1998

Papers

230

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37290592	Morphologic and molecular analysis of liver injury after SARS-CoV-2 vaccination reveals distinct characteristics.		2023
36382698	Antibody response to a third SARS-CoV-2 vaccine dose in recipients of an allogeneic haematopoietic cell transplantation.	Br J Haematol	2023
36379023	Aging drives Tet2+/- clonal hematopoiesis via IL-1 signaling.	Blood	2023
36315929	Prognostic Value of -Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia.	Journal of Clinical Oncology	2023
36184692	Cross-reactivity to glutamate carboxypeptidase III causes undesired salivary gland and kidney uptake of PSMA-targeted small-molecule radionuclide therapeutics.	European Journal of Nuclear Medicine and Molecular Imaging	2023
38026789	Prognostic Significance of Measurable Residual Disease Detection by Flow Cytometry in Autologous Stem Cell Apheresis Products in AML.		2023
37654971	Erratum: Anti-CD117 CAR TÂ cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells.		2023
37819374	Twisted: Escape of epitope-edited healthy cells from immune attack.		2023
37583386	Anti-CD117 CAR TÂ cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells.		2023
38091952	Circulating senescent myeloid cells infiltrate the brain and cause neurodegeneration in histiocytic disorders.	Immunity	2023
37479752	Haploidentical transplant with posttransplant cyclophosphamide vs matched related and unrelated donor transplant in acute myeloid leukemia and myelodysplastic neoplasm.		2023
37288872	Generation of a novel fully human non-superagonistic anti-CD28 antibody with efficient and safe T-cell co-stimulation properties.	MAbs	2023
37095207	Blocking the CD47-SIRPÎ± interaction reverses the disease phenotype in a polycythemia vera mouse model.		2023
36898087	Prospective validation of the prognostic relevance of CD34+CD38- AML stem cell frequency in the HOVON-SAKK132 trial.		2023
37336890	Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine.		2023
37335916	Chimeric antigen receptor T cell-based targeting of CD317 as a novel immunotherapeutic strategy against glioblastoma.	Neuro Oncol	2023
37081258	Ex vivo drug response heterogeneity reveals personalized therapeutic strategies for patients with multiple myeloma.	Nat Cancer	2023
37021540	Measurable residual disease-guided therapy in intermediate-risk acute myeloid leukemia patients is a valuable strategy in reducing allogeneic transplantation without negatively affecting survival.		2023
36494600	BRAF inhibitor treatment of classical hairy cell leukemia allows successful vaccination against SARS-CoV-2.		2023
37254629	Complication rates of peripherally inserted central catheters vs implanted ports in patients receiving systemic anticancer therapy: A retrospective cohort study.		2023
36690387	Diabetes insipidus and Guillain-BarrÃ©-like syndrome following CAR-T cell therapy: a case report.		2023
37109212	Indications and Outcomes of Patients Receiving Therapeutic Plasma Exchange under Critical Care Conditions: A Retrospective Eleven-Year Single-Center Study at a Tertiary Care Center.		2023
37099813	Humanized mouse models with endogenously developed human natural killer cells for inÂ vivo immunogenicity testing of HLA class I-edited iPSC-derived cells.		2023
34525198	IL-1 mediates microbiome-induced inflammaging of hematopoietic stem cells in mice.	Blood	2022
35461758	Retraction notice to "Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer" [Canc. Lett. 520 (2021) 385-399].	Cancer Lett	2022
36300090	Concordance in measurable residual disease result after first and second induction cycle in acute myeloid leukemia: An outcome- and cost-analysis.	Frontiers in Oncology	2022
35752964	Introducing innovative cellular therapies into the clinic: a 2-year retrospective experience of a chimeric antigen receptor T-cell programme at a single centre in Switzerland.	Swiss Med Wkly	2022
35747591	CAR T-cell Infusion Following Checkpoint Inhibition Can Induce Remission in Chemorefractory Post-transplant Lymphoproliferative Disorder of the CNS.	HemaSphere	2022
35487310	Enhanced AC133-specific CAR T cell therapy induces durable remissions in mice with metastatic small cell lung cancer.	Cancer Lett	2022
35736667	Addition of romiplostim to conditioning prior to HSCT allows chemotherapy reduction while maintaining engraftment levels.	Blood advances	2022
36201333	TLR1/2-stimulated DCs "prime" HSCs via IL-1Î².	Blood	2022
35718092	Comprehensive Validation of Diagnostic Next-Generation Sequencing Panels for Acute Myeloid Leukemia Patients.	J Mol Diagn	2022
36636430	Fulminant Cardiotoxicity in a Patient With Cardiac Lymphoma Treated With CAR-T Cells.		2022
34314497	Asymmetric organelle inheritance predicts human blood stem cell fate.	Blood	2022
35026842	TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms.	Blood advances	2022
34611894	Baseline creatinine predicts acute kidney injury during intensive therapy in transplant-eligible patients with acute myeloid leukaemia.	British Journal of Haematology	2022
35182191	Real-world outcomes in elderly ALL patients with and without allogeneic hematopoietic stem cell transplantation: a single-center evaluation over 10Â years.	Annals of Hematology	2022
34953042	The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed.	Cancer Medicine	2022
35008095	Proteomic identification of proliferation and progression markers in human polycythemia vera stem and progenitor cells.	Blood Adv	2022
35092892	Antibody Response to SARS-CoV-2 Vaccination in Patients following Allogeneic Hematopoietic Cell Transplantation.	Transplant Cell Ther	2022
35120614	A microbiome-macrophage-iron axis guides stressed hematopoietic stem cell fate.		2022
34750374	Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia.	Nature Communications	2021
34180543	Daratumumab in rituximab-refractory autoimmune haemolytic anaemia.	British Journal of Haematology	2021
34129016	Inflammation as a regulator of hematopoietic stem cell function in disease, aging, and clonal selection.	Journal of Experimental Medicine	2021
33704530	Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort.	Annals of Hematology	2021
33484750	Anti-CD117 immunotherapy to eliminate hematopoietic and leukemia stem cells.	Experimental Hematology	2021
33482122	The Tumor Profiler Study: integrated, multi-omic, functional tumor profiling for clinical decision support.	Cancer Cell	2021
33958797	BRAF<sup>V600E</sup>-induced senescence drives Langerhans cell histiocytosis pathophysiology.	Nat Med	2021
34053123	Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients.	European Journal of Haematology	2021
33574218	Reduced CXCL4/PF4 expression as a driver of increased human hematopoietic stem and progenitor cell proliferation in polycythemia vera.	Blood Cancer J	2021